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INTRODUCTION Multiple myeloma (MM) is a plasma cell neoplasmwith substantial morbidity
andmortality. A comprehensive description of the global burden of MM is needed to help
direct health policy, resource allocation, research, and patient care.
OBJECTIVE To describe the burden of MM and the availability of effective therapies for 21
world regions and 195 countries and territories from 1990 to 2016.
DESIGN AND SETTING We report incidence, mortality, and disability-adjusted life-year (DALY)
estimates from the Global Burden of Disease 2016 study. Data sources include vital
registration system, cancer registry, drug availability, and survey data for stem cell transplant
rates. We analyzed the contribution of aging, population growth, and changes in incidence
rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic
index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib
worldwide.
MAIN OUTCOMES ANDMEASURES Multiplemyelomamortality; incidence; years livedwith
disabilities; years of life lost; and DALYs by age, sex, country, and year.
RESULTS Worldwide in 2016 there were 138 509 (95% uncertainty interval [UI],
121 000-155 480) incident cases of MMwith an age-standardized incidence rate (ASIR) of 2.1
per 100000 persons (95%UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126%
globally and by 106% to 192% for all SDI quintiles. The 3 world regions with the highest ASIR
of MMwere Australasia, North America, andWestern Europe. Multiple myeloma caused 2.1
million (95%UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely
available in higher-income countries but is lacking in sub-Saharan Africa and parts of the
Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103
countries, respectively.
CONCLUSIONS AND RELEVANCE Incidence of MM is highly variable among countries but has
increased uniformly since 1990, with the largest increase in middle and low-middle SDI
countries. Access to effective care is very limited in many countries of low socioeconomic
development, particularly in sub-Saharan Africa. Global health policy priorities for MM are to
improve diagnostic and treatment capacity in low andmiddle income countries and to ensure
affordability of effective medications for every patient. Research priorities are to elucidate
underlying etiological factors explaining the heterogeneity in myeloma incidence.
JAMA Oncol. 2018;4(9):1221-1227. doi:10.1001/jamaoncol.2018.2128
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M ultiple myeloma (MM) is a clonal plasma cell neo-plasmwithsubstantialmorbidityandmortality, char-acterizedbyendorgandamage—renal impairment,hy-
percalcemia, lytic bony lesions, and anemia. With the
developmentofbetter therapies,myelomahaschangedfroman
untreatable ailment to one that is still not curable but treatable
with mostly outpatient therapy. Myeloma treatment has im-
proved substantially over the past decade. The first major ad-




teasome inhibitors (PIs).2 More recently, monoclonal antibod-
ies,suchasdaratumumabandelotuzumab,andhistonedeacety-
latingagents, suchaspanobinostat,havealsobeenapprovedby
the US Food and Drug Administration (FDA).2
Myeloma is unique as a cancer because basic diagnostic
testing includes only a complete blood cell count with differ-
ential, basicmetabolic panel; serumcalcium, serumandurine
proteinelectrophoresis;andosseoussurvey,allofwhichshould
be accessible in low- andmiddle-incomecountries (LMICs).3,4
Many advanced tests, such as the serum-free light-chain as-
say, fluorodeoxyglucose–positronemission tomography (FDG
PET) scan, cytogenetics, and fluorescence in situ hybridiza-
tion (FISH) may not be available. Because of this, resource-
stratified guidelines for the diagnosis and treatment of MM
havebeendeveloped.4Another unique feature ofmyeloma is
that treatment canbedelivered almost exclusively in the out-
patient setting (with the exception of ASCT).
Standard treatment for myeloma is largely dependent on
patient fitness andunderlyinghealth status. For those in good
health and younger than 70 to 75 years, the preferred treat-
ment for newly diagnosed patients with myeloma comprises
a triplet novel agent regimen, typically including an IMID and
PI in combinationwith glucocorticoids, followedbyASCTand
maintenance therapy with low-dose IMID or PI.5,6 For those
unable to undergo ASCT, standard therapy includes induc-
tion with novel agents and low-dose maintenance therapy.7
Despite improvements in the care of patients with my-
eloma, these advances have largely delivered better out-
comes to patients in high-income countries. In many LMICs,
delivery of cancer care is often hindered by lack of access to
general and specialized health care, diagnostics, and ad-
vanced treatments, like novel agents, radiationoncology, and
stem cell transplantation, leading to poor outcomes. In stud-
ies of patientswithmyeloma treated inNigeria, lack of access
to affordable health care, late presentation, and inadequate
treatmentwere suggested as common factors contributing to
poor outcomes, with a 5-year survival of only 7.6%.8,9
Necessarydata to informhealthpolicieswithrespect tomy-
elomaonaglobal level, includingcancercontroland implemen-
tationplans, arenotwidely available. These includedataon in-
cidence,mortality,andavailabilityofeffective therapiessuchas
IMIDs, PIs, andASCT. This study therefore aims todescribe the
globalburdenofmyelomafrom1990to2016byage,sex,andso-
ciodemographic index(SDI) (asummary indicatorof incomeper
capita,educationalattainment,andfertility)andtodescribe the






Flowcharts describing the process to estimate mortality, inci-
dence,prevalence,years livedwithdisability (YLDs),yearsof life
lost (YLLs), and disability-adjusted life-years (DALYs) can be
found in eFigures 1 and 2 in the Supplement. Methods for the
Global Burden of Disease (GBD) study and the cancer estima-




.org/gbd-2016/data-input-sources). The VR and CR data were





Health Problems, Tenth Revision (ICD-10) mapped to the GBD
cause “multiple myeloma” were C88 (“malignant
immunoproliferative diseases and certain other B-cell
lymphomas”) and C90 (“multiple myeloma and malignant
plasma cell neoplasms”). Cancer registry incidence data were
transformedtomortalityestimatesbyusingseparatelymodeled
mortality-to-incidenceratios(MIRs).TheVRdatawerecombined
with the mortality estimates that were derived from CR MM
incidence data and used as input for an ensemble model of
mixed-effects linear models and spatiotemporal Gaussian
process regression models for MM cause fractions and death
rates.14 Covariates used in the models can be found in the
Appendix (eTable 1 in theSupplement).Myelomamortalitywas
adjusted to fit into the separately estimated all-causemortality
inaprocesscalled“CodCorrect,”whichisanalgorithmthatscales
single causesofdeath to all-causemortality andchild causes to
parent causes.10 The YLLs were estimated by calculating the
difference between a standard life expectancy and the age at
death.13 Final MM mortality estimates were divided by MIR,
resulting in incidence estimates.
Key Points
Question What is the burden of multiple myeloma globally and by
country, how has it changed over time, and howwidely available
are treatments for this disease?
Findings Myeloma incident cases and deaths increased from
1990 to 2016, with middle-income countries contributing the
most to this increase. Treatment availability is very limited in
countries with low socioeconomic development.
Meaning Marked variation in myeloma incidence andmortality
across countries highlights the need to improve access to
diagnosis and effective therapy and to expand research on
etiological determinants of myeloma.
Research Original Investigation Global Burden of Multiple Myeloma
1222 JAMAOncology September 2018 Volume 4, Number 9 (Reprinted) jamaoncology.com
Downloaded From:  by a Rijksuniversiteit Groningen User  on 11/21/2018
Myeloma survival was estimated by scaling GBD loca-
tions between a theoretical best-case and worst-case sce-
nario using theMIR as a scaling factor. For each incidence co-
hort, 10-year prevalence was estimated using the modeled
survival. Ten-yearmyelomaprevalencewasdivided into4 se-
quelae: (1) diagnosis and treatment (7 months),15 (2) remis-
sion (remaining duration after taking into account the other
sequelae), (3) metastatic and/or disseminated phase (37
months),16 and (4) terminal phase (1 month). Each sequela
prevalence was multiplied with a distinct disability weight,
which can be found in eTable 2 in the Supplement, and these
were summed to generate YLDs.13 DALYs were calculated as
the sum of YLDs and YLLs.11 Rates are reported per 100000
person-yearswith a 95%uncertainty interval (UI) reported in
parentheses.For theagestandardization, theGBDworldpopu-
lation standard was used.17 For measuring availability of ef-
fective therapies, lenalidomideglobal approval informationas
of 2016 was provided by the Australian Therapeutic Goods
Administration.18 Bortezomib global approval was deter-
mined via personal communication with Takeda Oncology
(email communication; Takeda Oncology; May 3, 2018). Data
on stemcell transplant availabilitywere reportedusing aprior
publication by the World Bone Marrow Transplant Society.19
To estimate the effect of population growth on myeloma in-
cidence,we applied the population size of 2016 onto the rate,
sex, and age structure of 1990. To estimate the effect of aging
on incident cases, we applied the age structure of 2016 onto
the rate, sex distribution, and population size of 1990. To es-
timate the effect of changing age-specific incidence rates on
the incidentcases,weapplied the incidence rates for 1990onto
the population size and age structure of 2016.
Results
Dataused for theMMestimates included16005site-years from
a vital registration system and 2737 site-years from cancer reg-
istry data. In 2016 there were 138 509 (95% UI, 121 000-
155480) incident cases of MM, with an age-standardized inci-
dence rate (ASIR) of 2.1 per 100000 persons (95% UI, 1.8-2.3).
Multiple myelomawas responsible for 98437 (95%UI, 87383-
109815) deaths globally with an age-standardized death rate
(ASDR)of 1.5per100000persons (95%UI, 1.3-1.7).Multiplemy-
eloma was responsible for 2.1 million (95% UI, 1.9-2.3 million)
DALYsat theglobal level in2016,with anage-standardized rate
of 30.5 (95% UI, 27.4-33.9) DALYs per 100000 person-years
(eTable 3 in the Supplement). From 1990 to 2016,MM incident
cases increased by 126%, and deaths increased by 94% (eTable
4 in theSupplement).AmongSDIquintiles, the largest increase
(192%) was seen in middle SDI countries (from 7974 [95% UI,
7233-8821] in 1990to23273 [95%UI,21 136-26947] in2016).Of




the largest increase in incidentcases from1990to2016wasseen
inEastAsia(China,NorthKorea,andTaiwan),withariseof262%
(from4760[95%UI,4271-5575] in1990to17218[95%UI,14482-
19093] in 2016). The largest contributor to this increase was a
rise in age-specific incidence rates (contributing 157%), fol-
lowed by an aging population (contributing 85%) and popula-
tion growth (contributing 20%) (eTable 4 in the Supplement).
The3world regionswith thehighestASIRofMMwereAus-
tralasia (5.8;95%UI,4.4-6.5),high-incomeNorthAmerica (5.2;
95% UI, 4.7-6.5), and Western Europe (4.6; 95% UI, 3.7-5.5)
(eTable 3 in the Supplement). The 3 highest ASDR were seen
in high-incomeNorthAmerica (3.0; 95%UI, 2.6-3.6), Austral-
asia (2.8; 95% UI, 2.1-3.1), and Western Europe (2.6; 95% UI,
2.1-3.1). In termsof absolutenumbers,WesternEuropewas the
regionwith themost cases ofmyeloma for both sexes in 2016
(35433;95%UI,28272-42 151), followedbyhigh-incomeNorth
America (27003; 95%UI, 24 157-33637) andEast Asia (17 218;
95%UI, 14482-19093). Most deaths occurred inWestern Eu-
rope (22 060; 95% UI, 17 571-25 628), high-income North
America (15894;95%UI, 14059-19364), andSouthAsia (11 187;
95% UI, 8975-12 182) (see eTable 3 in the Supplement). The
countries with the most incident cases and deaths were the
UnitedStates (24407[95%UI,21812-30331] incidentcasesand
14212 [95%UI, 12 523-17 316] deaths), China ([16 537; 95%UI,
14 094-18 617] incident cases and 10 363 [95% UI, 9079-
11 898] deaths), and India (8 940 [95% UI, 7142-9710] inci-
dent cases and 8 715 [95% UI, 6990-9600] deaths) (incident
cases anddeaths: https://vizhub.healthdata.org/gbd-compare
/). TheASIR andASDRwere thehighest in high-income coun-
trieswithanalmost 10-folddifferencebetweencountrieswith
the lowest and the highest ASIR and ASDR (Figure 1; eFigure
3 in the Supplement). From 1990 to 2016, ASIRs rose in all SDI
quintiles except for the low SDI quintile, where they re-
mained stable (eFigure 4 in the Supplement). However, AS-
DRspeaked in thehigh-SDIquintile around theyear 2000and
havebeendeclining since.The same trendcanbe seen inhigh-
middleSDIcountries,withamore recentpeak inASDRsaround
2005 and declining rates since. ASDRs in the other SDI quin-
tiles have been rising (eFigure 5 in the Supplement). All re-
sults presented herein can also be found online at https:
//vizhub.healthdata.org/gbd-compare/.
Forstemcell transplantavailability, the top5countrieswith
thehighest rates (per 10millionpopulation) of stemcell trans-
plantation (for all indications, not just MM) were Israel (814),
Italy (671), Germany (665), Sweden (625), and the Nether-
lands (614) (Figure 2). Some regions of the world lack access
to stem cell transplantation entirely, particularly sub-
Saharan Africa (with the exception of South Africa). With re-
spect to drug availability, as of 2016, out of 195 countries and
territories, lenalidomide (Revlimid) had been approved in 73
countries andbortezomib (Velcade) in 103countries (Figure3).
Notably, neither drug has been approved inmost countries in
sub-Saharan Africa and some countries in Central Asia.
Discussion
Age-standardized incidence and death rates are highest in the
Australasian, North American, andWestern European popula-
tions. The world regions with the lowest age-standardized in-
cidenceofMMareAsia,Oceania,andsub-SaharanAfrica.These
Global Burden of Multiple Myeloma Original Investigation Research
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resultsare in linewiththoseofpriorstudiesthathaveshownthat
the reported incidence forhematologicmalignantneoplasms is
higher inhigh-incomecountries comparedwithLMIC20,21With
respect to these differences between incidence ofMM in high-
incomeandLMIC,a fulldiscussionof thepredisposition formy-
eloma isbeyond the scopeof this report, butknownrisk factors
includeantecedentdiagnosisofmonoclonalgammopathyofun-
determined significance or smolderingmyeloma, and possible
occupational risk factors.22 In addition, there have been re-
cently described autosomal germline mutations that can pre-
disposeapatient toMM.23At least someof thedifferences in in-
cidence may be due to lack of diagnostic abilities in lower SDI
countries comparedwith high SDI countries and do not neces-
sarily reflect differences in disease biology (eFigure 6 in the
Supplement shows amap of the SDI quintiles). Supporting this
hypothesis is the fact that the disease burden ofMM inAfrican
Americans in the United States is markedly higher than that of
European Americans in the United States, yet the disease bur-
den among Africans living in Africa is among the lowest in the
world,asshowninourstudyand inpreviousstudies.24,25Toex-
plain the heterogeneity in incidence, collaborative research
within the global oncology community is required on 2 fronts:
the basic research question of differences in underlying dis-
easebiology,andthepopulationhealthquestionofunderascer-
tainment.Despitetheheterogeneousgeographicalburdenofmy-
eloma, time trends show that incident cases of myeloma have
increased in all regions and havemore than doubled for all SDI
quintiles from 1990 to 2016. Global incident cases ofmyeloma
increasedby126%,withagingcontributing52.9%.This is in line
with the increase seen for other cancers that predominantly
affect an older population. Prostate cancer cases at the global
level, for example, increased by 217% from 1990 to 2013.26We
also showed that among SDI quintiles, the largest increase of
192% in incidence caseswas seen inmiddle-SDI countrieswith
an aging population and rising age-specific rates contributing
equally. Among regions, the largest increase of 262%was seen
in East Asia, mostly from a rise in age-specific incidence rates.
Given the lack of known strong risk factors for myeloma, re-
search in locationswithrapidlyrising incidenceratesmighthelp
to identify predisposing factors and guide future preventative
strategies.
We have also described an improvement in ASDRs for MM
from 1990 to 2016 in high-income SDI regions despite increas-
ing incidence rates, which is likely reflective of improvements
in treatments. Novel agents, such as PIs and IMIDs, in addition
tohigh-dosemelphalanandASCT,havechanged the therapeu-
tic landscape, with improvement in 5-year survival rates from
25.1% in 1975 to 1979 to 52.7% in 2009 in the United States.7,27
With respect to availability of effective therapies, we de-
scribedtheapproval statusofbortezomibandlenalidomideand
theavailabilityofASCTasasurrogatemeasure,althoughourabil-
ity to assess true “availability”—as determined by factors such
Figure 1. Age-Standardized Incidence Rate ofMultipleMyeloma
Age-standardized incidence
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Persian Gulf
Age-standardized incidence rate of multiple myeloma, both sexes, 2016. ATG
indicates Antigua and Barbuda; BRB, Barbados; COM, Comoros; DMA,
Dominica; FJI, Fiji; FSM, Federated States of Micronesia; GRD, Grenada; KIR,
Kiribati; LCA, Saint Lucia; MDV, Maldives; MHL, Marshall Islands; MLT, Malta;
MUS, Mauritius; TLS, Timor-Leste; TON, Tonga; TTO, Trinidad and Tobago; SGP,
Singapore; SLB, Solomon Islands; SYC, Seychelles; VCT, Saint Vincent and the
Grenadines; VUT, Vanuatu; andWSM, Samo (Formerly Western Samoa).
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ined in this analysis.28 Nonetheless, 2 drugs that are now con-
sideredstandardofcare, lenalidomideandbortezomib,havenot
been approved in some African andMiddle Eastern countries,
and it is notable that there areno stemcell transplant centers in
sub-Saharan Africa, with the exception of South Africa. Thus,
onaglobal level therearemarkeddiscrepancies in theavailabil-
ity of effective therapies. In addition to ensuring universal ac-
cess to health care, as specified in target 3.8 of the Sustainable
Development Goals, it is imperative to at least ensure access to
highly effective medications.29 Initiatives like the market ac-
cessagreementsnegotiatedbytheAmericanCancerSocietyand
theClintonHealthAccess InitiativewithPfizer IncandCipla Inc
to expand access to essential cancermedications are hopefully
reflective of improved affordability, as has been the case with
antiretroviral treatments for HIV/AIDS.30
Limitations
Limitations of our study are that data informing themodels to
estimate the burdenofmyelomaare often scarce, especially in
LMICswherevital registrationsystemsandcancer registriesare
lackingor cover only a small part of thepopulation. Theuncer-
taintyaroundourestimates in these locations is therefore large.
Supporting the development of cancer registries and expand-
ing vital registration systems in these areas are crucial. Unfor-
tunately, our attempts to obtain data on drug sales from phar-
maceutical companies were unsuccessful, and therefore we
could report only drug availability. Given the challenges of es-
timating access to generic drugs like thalidomide, we chose to
report approval rates of lenalidomideandbortezomibwith the
understanding that thalidomide might represent an effective
treatmentoptions incountries thathavenotapproved lenalido-
mide. Other questions, such as which drugs are available
throughgovernment-sponsoredhealthplans,whichphases of
thedisease thedrug isapproved in,whichcombinationsareap-
proved,werenot specifically examined, and thuswewere lim-
ited in making more definitive conclusions about drug “ac-
cess” beyond regulatory approval. As an important example,
within the European Union (EU), the European Medicines
Agency (EMA) is responsible for the authorization of medi-
cines inEUcountries. TheEMAhas approved lenalidomide for
use intheEU;however,membercountrieshave individuallyde-
cidedwhether thedrugwill bepaid forbygovernmentalhealth
insurance. Thus, although marketing approval may be pre-
sent, it doesnot guarantee that adrugwill be coveredby insur-
ancesor thatpatients canafford thecost.With respect to trans-
plantation,we reportedprior data analyzing global availability
of transplantation but did not have access to myeloma-
specific transplant rates.Further research isneeded to fullyde-
Figure 2. Stem-Cell Transplant Rate per 10Million, 2010
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Frequency of transplantation per 10million people, both allogeneic and
autologous transplant in 2010 as reported by Gratwohl et al.19 ATG indicates
Antigua and Barbuda; BRB, Barbados; COM, Comoros; DMA, Dominica; FJI, Fiji;
FSM, Federated States of Micronesia; GRD, Grenada; KIR, Kiribati; LCA, Saint
Lucia; MDV, Maldives; MHL, Marshall Islands; MLT, Malta; MUS, Mauritius; TLS,
Timor-Leste; TON, Tonga; TTO, Trinidad and Tobago; SGP, Singapore; SLB,
Solomon Islands; SYC, Seychelles; VCT, Saint Vincent and the Grenadines; VUT,
Vanuatu; andWSM, Samo (Formerly Western Samoa).
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scribedetails on the availability, access, and reimbursementof
effective treatments for myeloma.
Conclusions
Although more common in high SDI countries, myeloma is a
global disease, and there has been a marked increase in inci-
dent cases from 1990 to 2016, predominantly in middle SDI
countries andEastAsia.Approval for effectivedrugs and stem
cell transplantationoptions are lacking inmany low-SDI coun-
tries. Collaborative global efforts areneeded to ensure that ev-
ery patient with myeloma is being diagnosed and has access
to effective treatment. Further research is needed to deter-
mine the reasons behind the observed heterogeneity in dis-
ease burden.
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